trial

Effects of Neurocognitive and Social Cognitive Remediation in Patients at Ultra-High Risk of Psychosis

NCTId NCT02098408
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 146 (actual)
Sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Primary completion 2019-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
146 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-03
Primary completion
2019-02
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Cognitive RemediationStandard treatment

Sponsors

Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalLead Sponsor
Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINSCollaborator
Copenhagen Trial Unit, Center for Clinical Intervention ResearchCollaborator

Investigators

2
Merete Nordentoft, MD, PhD, MPHPrincipal Investigator
Louise Birkedal GlenthøjStudy Director

Sites

1 total
Copenhagen, Denmark

Facts & assertions

4 sourced
Enrollment
146
Phase
NA
Primary Completion Date
2019-02
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Remediation
drug
Standard treatment
drug
lead_sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
company
collaborator
Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS
company
Copenhagen Trial Unit, Center for Clinical Intervention Research
company
indication
Patients at Ultra-high Risk of Psychosis
indication
investigator
Merete Nordentoft, MD, PhD, MPH
person
Louise Birkedal Glenthøj
person